Figure 3: CZE separations of rituximab using running buffer of pH=5.2 with different concentration of EACA. Conditions: 400-1600 mM EACA ((a,): 400 mM, (b,): 800 mM, (c,): 1000 mM, (d,): 1600 mM, (e,): 800 mM), 2 mM TETA, 0.05% HPMC, capillary: 64.5 cm x 50 μm i.d., leff: 8.5 cm, sample was injected by 150 mbar.s at the anodic end of the capillary, closer to the detection window ("short end injection"), -15 kV, λ= 200 nm. The 10 mg/ml pharmaceutical product MabThera was tenfold diluted with water. in case of (e,): capillary: 30 cm x 50 μm i.d., leff: 21.5 cm, +15 kV, sample was injected further to the detection window (normal mode).